Molecular mechanisms of cardiac pathology in diabetes – Experimental insights

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1864, Issue 5, 2018, Pages 1949-1959

  Varma, U ^b   Koutsifeli, P ^a,b   Benson, V L ^a   Mellor, K M ^a,b,c   Delbridge, L M D ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Autophagy; Diabetes; Heart; Metabolism; Oxidative stress

Indexed keywords

BETA ADRENERGIC RECEPTOR; FAT DROPLET; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER; GLYCOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN;

AMPK SIGNALING; APOPTOSIS; AUTOPHOSPHORYLATION; BETA ADRENERGIC STIMULATION; CARDIAC MUSCLE CELL; CELL DEATH; CELL SURVIVAL; COMORBIDITY; DIABETIC CARDIOMYOPATHY; DIABETIC PATIENT; FATTY ACID OXIDATION; GENE DELETION; GENETIC MANIPULATION; GLUCOSE ABSORPTION; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; GLYCOGEN ANALYSIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN SIGNALING; LIPID STORAGE; METABOLIC DISORDER; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; SARCOLEMMA; SELECTIVE AUTOPHAGY; UPREGULATION; ADAPTATION; ANIMAL; AUTOPHAGY; BLOOD; CARDIAC MUSCLE; DIABETES MELLITUS; ENERGY METABOLISM; FIBROSIS; GLUCOSE BLOOD LEVEL; HEART VENTRICLE REMODELING; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ADAPTATION, PHYSIOLOGICAL; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; AUTOPHAGY; BLOOD GLUCOSE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHIES; ENERGY METABOLISM; FIBROSIS; HUMANS; INSULIN; LIPID DROPLETS; MYOCARDIUM; OXIDATIVE STRESS; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 85034611092     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2017.10.035     Document Type: Review

References (204)

1. Huynh, K., Bernardo, B.C., McMullen, J.R., Ritchie, R.H., Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol. Ther. 142 (2014), 375–415.
2. Lam, C.S., Diabetic cardiomyopathy: an expression of stage B heart failure with preserved ejection fraction. Diab. Vasc. Dis. Res. 12 (2015), 234–238.
3. Bugger, H., Abel, E.D., Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 57 (2014), 660–671.
4. Fisher, B.M., Gillen, G., Lindop, G.B., Dargie, H.J., Frier, B.M., Cardiac function and coronary arteriography in asymptomatic type 1 (insulin-dependent) diabetic patients: evidence for a specific diabetic heart disease. Diabetologia 29 (1986), 706–712.
5. Jia, G., Whaley-Connell, A., Sowers, J.R., Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia, 2017.
6. Dandamudi, S., Slusser, J., Mahoney, D.W., Redfield, M.M., Rodeheffer, R.J., Chen, H.H., The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota. J. Card. Fail. 20 (2014), 304–309.
7. Patil, V.C., Patil, H.V., Shah, K.B., Vasani, J.D., Shetty, P., Diastolic dysfunction in asymptomatic type 2 diabetes mellitus with normal systolic function. J. Cardiovasc. Dis. Res. 2 (2011), 213–222.
8. Shimabukuro, M., Higa, N., Asahi, T., Yamakawa, K., Oshiro, Y., Higa, M., Masuzaki, H., Impaired glucose tolerance, but not impaired fasting glucose, underlies left ventricular diastolic dysfunction. Diabetes Care 34 (2011), 686–690.
9. From, A.M., Scott, C.G., Chen, H.H., The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J. Am. Coll. Cardiol. 55 (2010), 300–305.
10. Liu, J.E., Palmieri, V., Roman, M.J., Bella, J.N., Fabsitz, R., Howard, B.V., Welty, T.K., Lee, E.T., Devereux, R.B., The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J. Am. Coll. Cardiol. 37 (2001), 1943–1949.
11. van Heerebeek, L., Hamdani, N., Handoko, M.L., Falcao-Pires, I., Musters, R.J., Kupreishvili, K., Ijsselmuiden, A.J., Schalkwijk, C.G., Bronzwaer, J.G., Diamant, M., Borbely, A., van der Velden, J., Stienen, G.J., Laarman, G.J., Niessen, H.W., Paulus, W.J., Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117 (2008), 43–51.
12. Nadeau, K.J., Regensteiner, J.G., Bauer, T.A., Brown, M.S., Dorosz, J.L., Hull, A., Zeitler, P., Draznin, B., Reusch, J.E., Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. J. Clin. Endocrinol. Metab. 95 (2010), 513–521.
13. Bradley, T.J., Slorach, C., Mahmud, F.H., Dunger, D.B., Deanfield, J., Deda, L., Elia, Y., Har, R.L., Hui, W., Moineddin, R., Reich, H.N., Scholey, J.W., Mertens, L., Sochett, E., Cherney, D.Z., Early changes in cardiovascular structure and function in adolescents with type 1 diabetes. Cardiovasc. Diabetol., 15, 2016, 31.
14. Diamant, M., Lamb, H.J., Groeneveld, Y., Endert, E.L., Smit, J.W., Bax, J.J., Romijn, J.A., de Roos, A., Radder, J.K., Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J. Am. Coll. Cardiol. 42 (2003), 328–335.
15. Jaffe, A.S., Spadaro, J.J., Schechtman, K., Roberts, R., Geltman, E.M., Sobel, B.E., Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. Am. Heart J. 108 (1984), 31–37.
16. Goyal, A., Agrawal, N., Ischemic preconditioning: interruption of various disorders. J. Saudi Heart Assoc. 29 (2017), 116–127.
17. Reichelt, M.E., Mellor, K.M., Bell, J.R., Chandramouli, C., Headrick, J.P., Delbridge, L.M., Sex, sex steroids, and diabetic cardiomyopathy: making the case for experimental focus. Am. J. Physiol. Heart Circ. Physiol. 305 (2013), H779–792.
18. Christopher, B.A., Huang, H.M., Berthiaume, J.M., McElfresh, T.A., Chen, X., Croniger, C.M., Muzic, R.F. Jr., Chandler, M.P., Myocardial insulin resistance induced by high fat feeding in heart failure is associated with preserved contractile function. Am. J. Phys. Heart Circ. Phys. 299 (2010), H1917–1927.
19. Rennison, J.H., McElfresh, T.A., Chen, X., Anand, V.R., Hoit, B.D., Hoppel, C.L., Chandler, M.P., Prolonged exposure to high dietary lipids is not associated with lipotoxicity in heart failure. J. Mol. Cell. Cardiol. 46 (2009), 883–890.
20. Rennison, J.H., McElfresh, T.A., Okere, I.C., Vazquez, E.J., Patel, H.V., Foster, A.B., Patel, K.K., Chen, Q., Hoit, B.D., Tserng, K.Y., Hassan, M.O., Hoppel, C.L., Chandler, M.P., High-fat diet postinfarction enhances mitochondrial function and does not exacerbate left ventricular dysfunction. Am. J. Phys. Heart Circ. Phys. 292 (2007), H1498–1506.
21. Shimizu, I., Minamino, T., Toko, H., Okada, S., Ikeda, H., Yasuda, N., Tateno, K., Moriya, J., Yokoyama, M., Nojima, A., Koh, G.Y., Akazawa, H., Shiojima, I., Kahn, C.R., Abel, E.D., Komuro, I., Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J. Clin. Invest. 120 (2010), 1506–1514.
22. Stanley, W.C., Lopaschuk, G.D., McCormack, J.G., Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc. Res. 34 (1997), 25–33.
23. Yang, L., Zhao, D., Ren, J., Yang, J., Endoplasmic reticulum stress and protein quality control in diabetic cardiomyopathy. Biochim. Biophys. Acta 1852 (2015), 209–218.
24. Mellor, K.M., Brimble, M.A., Delbridge, L.M., Glucose as an agent of post-translational modification in diabetes—new cardiac epigenetic insights. Life Sci. 129 (2015), 48–53.
25. Bidasee, K.R., Nallani, K., Yu, Y., Cocklin, R.R., Zhang, Y., Wang, M., Dincer, U.D., Besch, H.R. Jr., Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/calcium-release channels. Diabetes 52 (2003), 1825–1836.
26. 2 +-ATPase. Diabetes 53 (2004), 463–473.
27. McLarty, J.L., Marsh, S.A., Chatham, J.C., Post-translational protein modification by O-linked N-acetyl-glucosamine: its role in mediating the adverse effects of diabetes on the heart. Life Sci. 92 (2013), 621–627.
28. 2 + handling and myofilament responsiveness. Am. J. Physiol. Heart Circ. Physiol. 302 (2012), H964–972.
29. Pereira, L., Ruiz-Hurtado, G., Rueda, A., Mercadier, J.J., Benitah, J.P., Gomez, A.M., Calcium signaling in diabetic cardiomyocytes. Cell Calcium 56 (2014), 372–380.
30. Mishra, P.K., Ying, W., Nandi, S.S., Bandyopadhyay, G.K., Patel, K.K., Mahata, S.K., Diabetic cardiomyopathy: an immunometabolic perspective. Front. Endocrinol. (Lausanne), 8, 2017, 72.
31. Taegtmeyer, H., Wilson, C.R., Razeghi, P., Sharma, S., Metabolic energetics and genetics in the heart. Ann. N. Y. Acad. Sci. 1047 (2005), 208–218.
32. Abel, E.D., Glucose transport in the heart. Front. Biosci. 9 (2004), 201–215.
33. Szablewski, L., Glucose transporters in healthy heart and in cardiac disease. Int. J. Cardiol. 230 (2017), 70–75.
34. Song, P., Onishi, A., Koepsell, H., Vallon, V., Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. Expert Opin. Ther. Targets 20 (2016), 1109–1125.
35. Banerjee, S.K., McGaffin, K.R., Pastor-Soler, N.M., Ahmad, F., SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc. Res. 84 (2009), 111–118.
36. Chen, Y., Du, J., Zhao, Y.T., Zhang, L., Lv, G., Zhuang, S., Qin, G., Zhao, T.C., Histone deacetylase (HDAC) inhibition improves myocardial function and prevents cardiac remodeling in diabetic mice. Cardiovasc. Diabetol., 14, 2015, 99.
37. Shao, D., Tian, R., Glucose transporters in cardiac metabolism and hypertrophy. Compr. Physiol. 6 (2015), 331–351.
38. Mellor, K.M., Ritchie, R.H., Davidoff, A.J., Delbridge, L.M.D., Elevated dietary sugar and the heart: experimental models and myocardial remodeling. Can. J. Physiol. Pharmacol. 88 (2010), 525–540.
39. Mellor, K.M., Bell, J.R., Wendt, I.R., Davidoff, A.J., Ritchie, R.H., Delbridge, L.M., Fructose modulates cardiomyocyte excitation-contraction coupling and Ca(2)(+) handling in vitro. PLoS One, 6, 2011, e25204.
40. Lal, S., Randall, W.C., Taylor, A.H., Kappler, F., Walker, M., Brown, T.R., Szwergold, B.S., Fructose-3-phosphate production and polyol pathway metabolism in diabetic rat hearts. Metabolism 46 (1997), 1333–1338.
41. Kashiwagi, A., Obata, T., Suzaki, M., Takagi, Y., Kida, Y., Ogawa, T., Tanaka, Y., Asahina, T., Ikebuchi, M., Saeki, Y. et al., Increase in cardiac muscle fructose content in streptozotocin-induced diabetic rats. Metabolism 41 (1992), 1041–1046.
42. Delbridge, L.M., Benson, V.L., Ritchie, R.H., Mellor, K.M., Diabetic cardiomyopathy: the case for a role of fructose in disease etiology. Diabetes 65 (2016), 3521–3528.
43. Buchanan, J., Mazumder, P.K., Hu, P., Chakrabarti, G., Roberts, M.W., Yun, U.J., Cooksey, R.C., Litwin, S.E., Abel, E.D., Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 146 (2005), 5341–5349.
44. Hue, L., Taegtmeyer, H., The Randle cycle revisited: a new head for an old hat. Am. J. Phys. Endocrinol. Metab. 297 (2009), E578–591.
45. Le Page, L.M., Rider, O.J., Lewis, A.J., Ball, V., Clarke, K., Johansson, E., Carr, C.A., Heather, L.C., Tyler, D.J., Increasing pyruvate dehydrogenase flux as a treatment for diabetic cardiomyopathy: a combined 13C hyperpolarized magnetic resonance and echocardiography study. Diabetes 64 (2015), 2735–2743.
46. Nicholl, T.A., Lopaschuk, G.D., McNeill, J.H., Effects of free fatty acids and dichloroacetate on isolated working diabetic rat heart. Am. J. Phys. 261 (1991), H1053–1059.
47. How, O.J., Larsen, T.S., Hafstad, A.D., Khalid, A., Myhre, E.S., Murray, A.J., Boardman, N.T., Cole, M., Clarke, K., Severson, D.L., Aasum, E., Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice. Arch. Physiol. Biochem. 113 (2007), 211–220.
48. Bayeva, M., Sawicki, K.T., Ardehali, H., Taking diabetes to heart—deregulation of myocardial lipid metabolism in diabetic cardiomyopathy. J. Am. Heart Assoc., 2, 2013, e000433.
49. Taegtmeyer, H., McNulty, P., Young, M.E., Adaptation and maladaptation of the heart in diabetes: part I: general concepts. Circulation 105 (2002), 1727–1733.
50. Finck, B.N., Lehman, J.J., Leone, T.C., Welch, M.J., Bennett, M.J., Kovacs, A., Han, X., Gross, R.W., Kozak, R., Lopaschuk, G.D., Kelly, D.P., The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 109 (2002), 121–130.
51. Cha, D.R., Han, J.Y., Su, D.M., Zhang, Y., Fan, X., Breyer, M.D., Guan, Y., Peroxisome proliferator-activated receptor-alpha deficiency protects aged mice from insulin resistance induced by high-fat diet. Am. J. Nephrol. 27 (2007), 479–482.
52. Aasum, E., Belke, D.D., Severson, D.L., Riemersma, R.A., Cooper, M., Andreassen, M., Larsen, T.S., Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am. J. Physiol. Heart Circ. Physiol. 283 (2002), H949–957.
53. Carley, A.N., Semeniuk, L.M., Shimoni, Y., Aasum, E., Larsen, T.S., Berger, J.P., Severson, D.L., Treatment of type 2 diabetic db/db mice with a novel PPARgamma agonist improves cardiac metabolism but not contractile function. Am. J. Phys. Endocrinol. Metab. 286 (2004), E449–455.
54. Sharma, S., Taliyan, R., Histone deacetylase inhibitors: future therapeutics for insulin resistance and type 2 diabetes. Pharmacol. Res. Off. J. Ital. Pharmacol. Soc. 113 (2016), 320–326.
55. Lee, T.I., Kao, Y.H., Tsai, W.C., Chung, C.C., Chen, Y.C., Chen, Y.J., HDAC inhibition modulates cardiac PPARs and fatty acid metabolism in diabetic cardiomyopathy. PPAR Res., 2016, 2016, 5938740.
56. Riehle, C., Abel, E.D., Insulin signaling and heart failure. Circ. Res. 118 (2016), 1151–1169.
57. Song, R., Peng, W., Zhang, Y., Lv, F., Wu, H.K., Guo, J., Cao, Y., Pi, Y., Zhang, X., Jin, L., Zhang, M., Jiang, P., Liu, F., Meng, S., Cao, C.M., Xiao, R.P., Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders. Nature 494 (2013), 375–379.
58. Liu, F., Song, R., Feng, Y., Guo, J., Chen, Y., Zhang, Y., Chen, T., Wang, Y., Huang, Y., Li, C.Y., Cao, C., Zhang, Y., Hu, X., Xiao, R.P., Upregulation of MG53 induces diabetic cardiomyopathy through transcriptional activation of peroxisome proliferation-activated receptor alpha. Circulation 131 (2015), 795–804.
59. Zhang, Y., Wu, H.K., Lv, F., Xiao, R.P., MG53, biological function and potential as a therapeutic target. Mol. Pharmacol. 92 (2017), 211–218.
60. Belke, D.D., Betuing, S., Tuttle, M.J., Graveleau, C., Young, M.E., Pham, M., Zhang, D., Cooksey, R.C., McClain, D.A., Litwin, S.E., Taegtmeyer, H., Severson, D., Kahn, C.R., Abel, E.D., Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J. Clin. Invest. 109 (2002), 629–639.
61. Boudina, S., Bugger, H., Sena, S., O'Neill, B.T., Zaha, V.G., Ilkun, O., Wright, J.J., Mazumder, P.K., Palfreyman, E., Tidwell, T.J., Theobald, H., Khalimonchuk, O., Wayment, B., Sheng, X., Rodnick, K.J., Centini, R., Chen, D., Litwin, S.E., Weimer, B.E., Abel, E.D., Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 119 (2009), 1272–1283.
62. Bugger, H., Riehle, C., Jaishy, B., Wende, A.R., Tuinei, J., Chen, D., Soto, J., Pires, K.M., Boudina, S., Theobald, H.A., Luptak, I., Wayment, B., Wang, X., Litwin, S.E., Weimer, B.C., Abel, E.D., Genetic loss of insulin receptors worsens cardiac efficiency in diabetes. J. Mol. Cell. Cardiol. 52 (2012), 1019–1026.
63. Qi, Y., Xu, Z., Zhu, Q., Thomas, C., Kumar, R., Feng, H., Dostal, D.E., White, M.F., Baker, K.M., Guo, S., Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38alpha MAPK during insulin resistance. Diabetes 62 (2013), 3887–3900.
64. Shum, M., Bellmann, K., St-Pierre, P., Marette, A., Pharmacological inhibition of S6K1 increases glucose metabolism and Akt signalling in vitro and in diet-induced obese mice. Diabetologia 59 (2016), 592–603.
65. Liu, H., Liu, H.Y., Jiang, Y.N., Li, N., Protective effect of thymoquinone improves cardiovascular function, and attenuates oxidative stress, inflammation and apoptosis by mediating the PI3K/Akt pathway in diabetic rats. Mol. Med. Rep. 13 (2016), 2836–2842.
66. Chen, Q., Xu, T., Li, D., Pan, D., Wu, P., Luo, Y., Ma, Y., Liu, Y., JNK/PI3K/Akt signaling pathway is involved in myocardial ischemia/reperfusion injury in diabetic rats: effects of salvianolic acid A intervention. Am. J. Transl. Res. 8 (2016), 2534–2548.
67. Ritchie, R.H., Love, J.E., Huynh, K., Bernardo, B.C., Henstridge, D.C., Kiriazis, H., Tham, Y.K., Sapra, G., Qin, C., Cemerlang, N., Boey, E.J., Jandeleit-Dahm, K., Du, X.J., McMullen, J.R., Enhanced phosphoinositide 3-kinase(p110alpha) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes. Diabetologia 55 (2012), 3369–3381.
68. Prakoso, D., DeBlasio, M.J., Qin, C., Rosli, S., Kiriazis, H., Qian, H., Du, X.J., Weeks, K.L., Gregorevic, P., McMullen, J.R., Ritchie, R.H., Phosphoinositide 3-kinase (p110alpha) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction. Clin. Sci. (Lond.) 131 (2017), 1345–1360.
69. Zhu, Y., Pereira, R.O., O'Neill, B.T., Riehle, C., Ilkun, O., Wende, A.R., Rawlings, T.A., Zhang, Y.C., Zhang, Q., Klip, A., Shiojima, I., Walsh, K., Abel, E.D., Cardiac PI3K-Akt impairs insulin-stimulated glucose uptake independent of mTORC1 and GLUT4 translocation. Mol. Endocrinol. 27 (2013), 172–184.
70. Abdurrachim, D., Nabben, M., Hoerr, V., Kuhlmann, M.T., Bovenkamp, P., Ciapaite, J., Geraets, I.M.E., Coumans, W., Luiken, J., Glatz, J.F.C., Schafers, M., Nicolay, K., Faber, C., Hermann, S., Prompers, J.J., Diabetic db/db mice do not develop heart failure upon pressure overload: a longitudinal in vivo PET, MRI, and MRS study on cardiac metabolic, structural, and functional adaptations. Cardiovasc. Res. 113 (2017), 1148–1160.
71. Brainard, R.E., Watson, L.J., Demartino, A.M., Brittian, K.R., Readnower, R.D., Boakye, A.A., Zhang, D., Hoetker, J.D., Bhatnagar, A., Baba, S.P., Jones, S.P., High fat feeding in mice is insufficient to induce cardiac dysfunction and does not exacerbate heart failure. PLoS One, 8, 2013, e83174.
72. Chess, D.J., Khairallah, R.J., O'Shea, K.M., Xu, W., Stanley, W.C., A high-fat diet increases adiposity but maintains mitochondrial oxidative enzymes without affecting development of heart failure with pressure overload. Am. J. Phys. Heart Circ. Phys. 297 (2009), H1585–1593.
73. Grahame Hardie, D., AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease. J. Intern. Med. 276 (2014), 543–559.
74. Bairwa, S.C., Parajuli, N., Dyck, J.R., The role of AMPK in cardiomyocyte health and survival. Biochim. Biophys. Acta 1862 (2016), 2199–2210.
75. Russell, R.R. 3rd, Bergeron, R., Shulman, G.I., Young, L.H., Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am. J. Phys. 277 (1999), H643–649.
76. Lee, C.T., Ussher, J.R., Mohammad, A., Lam, A., Lopaschuk, G.D., 5′-AMP-activated protein kinase increases glucose uptake independent of GLUT4 translocation in cardiac myocytes. Can. J. Physiol. Pharmacol. 92 (2014), 307–314.
77. Jorgensen, S.B., Nielsen, J.N., Birk, J.B., Olsen, G.S., Viollet, B., Andreelli, F., Schjerling, P., Vaulont, S., Hardie, D.G., Hansen, B.F., Richter, E.A., Wojtaszewski, J.F., The alpha2-5'AMP-activated protein kinase is a site 2 glycogen synthase kinase in skeletal muscle and is responsive to glucose loading. Diabetes 53 (2004), 3074–3081.
78. Halse, R., Fryer, L.G., McCormack, J.G., Carling, D., Yeaman, S.J., Regulation of glycogen synthase by glucose and glycogen: a possible role for AMP-activated protein kinase. Diabetes 52 (2003), 9–15.
79. McBride, A., Ghilagaber, S., Nikolaev, A., Hardie, D.G., The glycogen-binding domain on the AMPK beta subunit allows the kinase to act as a glycogen sensor. Cell Metab. 9 (2009), 23–34.
80. Polekhina, G., Gupta, A., Michell, B.J., van Denderen, B., Murthy, S., Feil, S.C., Jennings, I.G., Campbell, D.J., Witters, L.A., Parker, M.W., Kemp, B.E., Stapleton, D., AMPK beta subunit targets metabolic stress sensing to glycogen. Curr. Biol. CB 13 (2003), 867–871.
81. An, H., He, L., Current understanding of metformin effect on the control of hyperglycemia in diabetes. J. Endocrinol. 228 (2016), R97–106.
82. Petrie, J.R., Chaturvedi, N., Ford, I., Brouwers, M., Greenlaw, N., Tillin, T., Hramiak, I., Hughes, A.D., Jenkins, A.J., Klein, B.E.K., Klein, R., Ooi, T.C., Rossing, P., Stehouwer, C.D.A., Sattar, N., Colhoun, H.M., R.S. Group, Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 5 (2017), 597–609.
83. Verma, S., McNeill, J.H., Metformin improves cardiac function in isolated streptozotocin-diabetic rat hearts. Am. J. Phys. 266 (1994), H714–719.
84. Xie, Z., Lau, K., Eby, B., Lozano, P., He, C., Pennington, B., Li, H., Rathi, S., Dong, Y., Tian, R., Kem, D., Zou, M.H., Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 60 (2011), 1770–1778.
85. Daniels, A., van Bilsen, M., Janssen, B.J., Brouns, A.E., Cleutjens, J.P., Roemen, T.H., Schaart, G., van der Velden, J., van der Vusse, G.J., van Nieuwenhoven, F.A., Impaired cardiac functional reserve in type 2 diabetic db/db mice is associated with metabolic, but not structural, remodelling. Acta Physiol (Oxford) 200 (2010), 11–22.
86. Tabbi-Anneni, I., Buchanan, J., Cooksey, R.C., Abel, E.D., Captopril normalizes insulin signaling and insulin-regulated substrate metabolism in obese (ob/ob) mouse hearts. Endocrinology 149 (2008), 4043–4050.
87. Kewalramani, G., An, D., Kim, M.S., Ghosh, S., Qi, D., Abrahani, A., Pulinilkunnil, T., Sharma, V., Wambolt, R.B., Allard, M.F., Innis, S.M., Rodrigues, B., AMPK control of myocardial fatty acid metabolism fluctuates with the intensity of insulin-deficient diabetes. J. Mol. Cell. Cardiol. 42 (2007), 333–342.
88. He, C., Zhu, H., Li, H., Zou, M.H., Xie, Z., Dissociation of Bcl-2-Beclin1 complex by activated AMPK enhances cardiac autophagy and protects against cardiomyocyte apoptosis in diabetes. Diabetes 62 (2013), 1270–1281.
89. Scognamiglio, R., Avogaro, A., Casara, D., Crepaldi, C., Marin, M., Palisi, M., Mingardi, R., Erle, G., Fasoli, G., Dalla Volta, S., Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 31 (1998), 404–412.
90. Paolillo, S., Rengo, G., Pagano, G., Pellegrino, T., Savarese, G., Femminella, G.D., Tuccillo, M., Boemio, A., Attena, E., Formisano, R., Petraglia, L., Scopacasa, F., Galasso, G., Leosco, D., Trimarco, B., Cuocolo, A., Perrone-Filardi, P., Impact of diabetes on cardiac sympathetic innervation in patients with heart failure: a 123I meta-iodobenzylguanidine (123I MIBG) scintigraphic study. Diabetes Care 36 (2013), 2395–2401.
91. Gotzsche, O., The adrenergic beta-receptor adenylate cyclase system in heart and lymphocytes from streptozotocin-diabetic rats. In vivo and in vitro evidence for a desensitized myocardial beta-receptor. Diabetes 32 (1983), 1110–1116.
92. Sundaresan, P.R., Sharma, V.K., Gingold, S.I., Banerjee, S.P., Decreased beta-adrenergic receptors in rat heart in streptozotocin-induced diabetes: role of thyroid hormones. Endocrinology 114 (1984), 1358–1363.
93. Savarese, J.J., Berkowitz, B.A., beta-Adrenergic receptor decrease in diabetic rat hearts. Life Sci. 25 (1979), 2075–2078.
94. Heyliger, C.E., Pierce, G.N., Singal, P.K., Beamish, R.E., Dhalla, N.S., Cardiac alpha- and beta-adrenergic receptor alterations in diabetic cardiomyopathy. Basic Res. Cardiol. 77 (1982), 610–618.
95. Nishio, Y., Kashiwagi, A., Kida, Y., Kodama, M., Abe, N., Saeki, Y., Shigeta, Y., Deficiency of cardiac beta-adrenergic receptor in streptozocin-induced diabetic rats. Diabetes 37 (1988), 1181–1187.
96. Cook, R.F., Bussey, C.T., Mellor, K.M., Cragg, P.A., Lamberts, R.R., beta1-Adrenoceptor, but not beta2-adrenoceptor, subtype regulates heart rate in type 2 diabetic rats in vivo. Exp. Physiol. 102 (2017), 911–923.
97. Wang, Q., Liu, Y., Fu, Q., Xu, B., Zhang, Y., Kim, S., Tan, R., Barbagallo, F., West, T., Anderson, E., Wei, W., Abel, E.D., Xiang, Y.K., Inhibiting insulin-mediated beta2-adrenergic receptor activation prevents diabetes-associated cardiac dysfunction. Circulation 135 (2017), 73–88.
98. Myagmar, B.E., Flynn, J.M., Cowley, P.M., Swigart, P.M., Montgomery, M.D., Thai, K., Nair, D., Gupta, R., Deng, D.X., Hosoda, C., Melov, S., Baker, A.J., Simpson, P.C., Adrenergic receptors in individual ventricular myocytes: the Beta-1 and alpha-1B are in all cells, the alpha-1A is in a subpopulation, and the Beta-2 and Beta-3 are mostly absent. Circ. Res. 120 (2017), 1103–1115.
99. Morisco, C., Condorelli, G., Trimarco, V., Bellis, A., Marrone, C., Sadoshima, J., Trimarco, B., Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes. Circ. Res. 96 (2005), 180–188.
100. Mangmool, S., Denkaew, T., Phosri, S., Pinthong, D., Parichatikanond, W., Shimauchi, T., Nishida, M., Sustained betaAR stimulation mediates cardiac insulin resistance in a PKA-dependent manner. Mol. Endocrinol. 30 (2016), 118–132.
101. Fu, Q., Xu, B., Parikh, D., Cervantes, D., Xiang, Y.K., Insulin induces IRS2-dependent and GRK2-mediated beta2AR internalization to attenuate betaAR signaling in cardiomyocytes. Cell. Signal. 27 (2015), 707–715.
102. Fu, Q., Wang, Q., Xiang, Y.K., Insulin and beta adrenergic receptor signaling: crosstalk in heart. Trends Endocrinol. Metab. 28 (2017), 416–427.
103. Mangmool, S., Denkaew, T., Parichatikanond, W., Kurose, H., beta-Adrenergic receptor and insulin resistance in the heart. Biomol. Ther. 25 (2017), 44–56.
104. Chandramouli, C., Varma, U., Stevens, E.M., Xiao, R.P., Stapleton, D.I., Mellor, K.M., Delbridge, L.M., Myocardial glycogen dynamics: new perspectives on disease mechanisms. Clin. Exp. Pharmacol. Physiol. 42 (2015), 415–425.
105. Ryu, J.H., Drain, J., Kim, J.H., McGee, S., Gray-Weale, A., Waddington, L., Parker, G.J., Hargreaves, M., Yoo, S.H., Stapleton, D., Comparative structural analyses of purified glycogen particles from rat liver, human skeletal muscle and commercial preparations. Int. J. Biol. Macromol. 45 (2009), 478–482.
106. Kokubun, E., Hirabara, S.M., Fiamoncini, J., Curi, R., Haebisch, H., Changes of glycogen content in liver, skeletal muscle, and heart from fasted rats. Cell Biochem. Funct. 27 (2009), 488–495.
107. Gannon, M.C., Nuttall, F.Q., Effect of prolonged starvation on glycogen synthase and glycogen synthase phosphatase activity in rat heart. J. Nutr. 114 (1984), 2147–2154.
108. He, J., Kelley, D.E., Muscle glycogen content in type 2 diabetes mellitus. Am. J. Physiol. Endocrinol. Metab. 287 (2004), E1002–1007.
109. Thorburn, A.W., Gumbiner, B., Bulacan, F., Brechtel, G., Henry, R.R., Multiple defects in muscle glycogen synthase activity contribute to reduced glycogen synthesis in non-insulin dependent diabetes mellitus. J. Clin. Invest. 87 (1991), 489–495.
110. Rizza, R.A., Crass, M.F. 3rd, Shipp, J.C., Effect of insulin treatment in vivo on heart glycerides and glycogen of alloxan-diabetic rats. Metab. Clin. Exp. 20 (1971), 539–543.
111. Penpargkul, S., Schaible, T., Yipintsoi, T., Scheuer, J., The effect of diabetes on performance and metabolism of rat hearts. Circ. Res. 47 (1980), 911–921.
112. Nakao, M., Matsubara, T., Sakamoto, N., Effects of diabetes on cardiac glycogen metabolism in rats. Heart Vessel. 8 (1993), 171–175.
113. Miller, T.B. Jr., Altered regulation of cardiac glycogen metabolism in spontaneously diabetic rats. Am. J. Phys. 245 (1983), E379–383.
114. Malfitano, C., de Souza Junior, A.L., Carbonaro, M., Bolsoni-Lopes, A., Figueroa, D., de Souza, L.E., Silva, K.A., Consolim-Colombo, F., Curi, R., Irigoyen, M.C., Glucose and fatty acid metabolism in infarcted heart from streptozotocin-induced diabetic rats after 2 weeks of tissue remodeling. Cardiovasc. Diabetol., 14, 2015, 149.
115. Lebkova, N.P., Kolesova, O.E., Gorbunova, V.D., Bobkov Iu, I., Petrovich Iu, A., Intracellular transformation of fatty acids into glycogen in alloxan diabetic rats, based on electron autoradiographic data. Biull. Eksp. Biol. Med. 98 (1984), 734–736.
116. Lebkova, N.P., Bondarenko, M.F., Kolesova, O.E., Azarian, G.P., Ultrastructural manifestations of early metabolic disorders in the myocardium of dogs with alloxan diabetes. Biull. Eksp. Biol. Med. 89 (1980), 614–617.
117. Laughlin, M.R., Petit, W.A. Jr., Shulman, R.G., Barrett, E.J., Measurement of myocardial glycogen synthesis in diabetic and fasted rats. Am. J. Phys. 258 (1990), E184–190.
118. Kraupp, O., Adler-Kastner, L., Niessner, H., Plank, B., The effects of starvation and of acute and chronic alloxan diabetes on myocardial substrate levels and on liver glycogen in the rat in vivo. Eur. J. Biochem. 2 (1967), 197–214.
119. Hsiao, Y.C., Suzuki, K., Abe, H., Toyota, T., Ultrastructural alterations in cardiac muscle of diabetic BB Wistar rats, Virchows Archiv A. Pathol. Anat. Histopathol. 411 (1987), 45–52.
120. Higuchi, M., Miyagi, K., Nakasone, J., Sakanashi, M., Role of high glycogen in underperfused diabetic rat hearts with added norepinephrine. J. Cardiovasc. Pharmacol. 26 (1995), 899–907.
121. Dervisevik, M., Dinevska-Kovkarovska, S., Dimitrovska, M., Cipanovska, N., Miova, B., High dose of aspirin moderates diabetes-induced changes of heart glycogen/glucose metabolism in rats. J. Physiol. Sci. JPS 64 (2014), 411–420.
122. Chen, V., Ianuzzo, C.D., Fong, B.C., Spitzer, J.J., The effects of acute and chronic diabetes on myocardial metabolism in rats. Diabetes 33 (1984), 1078–1084.
123. Bhimji, S., Godin, D.V., McNeill, J.H., Myocardial ultrastructural changes in alloxan-induced diabetes in rabbits. Acta Anat. 125 (1986), 195–200.
124. Alfarano, C., Suffredini, S., Fantappie, O., Mugelli, A., Cerbai, E., Manni, M.E., Raimondi, L., The effect of losartan treatment on the response of diabetic cardiomyocytes to ATP depletion. Pharmacol. Res. 63 (2011), 225–232.
125. Shearer, J., Ross, K.D., Hughey, C.C., Johnsen, V.L., Hittel, D.S., Severson, D.L., Exercise training does not correct abnormal cardiac glycogen accumulation in the db/db mouse model of type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 301 (2011), E31–39.
126. Sakakibara, M., Hirashiki, A., Cheng, X.W., Bando, Y., Ohshima, K., Okumura, T., Funahashi, H., Ohshima, S., Murohara, T., Association of diabetes mellitus with myocardial collagen accumulation and relaxation impairment in patients with dilated cardiomyopathy. Diabetes Res. Clin. Pract. 92 (2011), 348–355.
127. Rosen, P., Herberg, L., Reinauer, H., Different types of postinsulin receptor defects contribute to insulin resistance in hearts of obese Zucker rats. Endocrinology 119 (1986), 1285–1291.
128. Reyes, M., Steinhelper, M.E., Alvarez, J.A., Escobedo, D., Pearce, J., Valvano, J.W., Pollock, B.H., Wei, C.L., Kottam, A., Altman, D., Bailey, S., Thomsen, S., Lee, S., Colston, J.T., Oh, J.H., Freeman, G.L., Feldman, M.D., Impact of physiological variables and genetic background on myocardial frequency-resistivity relations in the intact beating murine heart. Am. J. Phys. Heart Circ. Phys. 291 (2006), H1659–1669.
129. Povlsen, J.A., Lofgren, B., Dalgas, C., Birkler, R.I., Johannsen, M., Stottrup, N.B., Botker, H.E., Protection against myocardial ischemia-reperfusion injury at onset of type 2 diabetes in Zucker diabetic fatty rats is associated with altered glucose oxidation. PLoS One, 8, 2013, e64093.
130. Plante, E., Menaouar, A., Danalache, B.A., Broderick, T.L., Jankowski, M., Gutkowska, J., Treatment with brain natriuretic peptide prevents the development of cardiac dysfunction in obese diabetic db/db mice. Diabetologia 57 (2014), 1257–1267.
131. Liang, J.L., Feng, Z.K., Liu, X.Y., Lin, Q.X., Fu, Y.H., Shan, Z.X., Zhu, J.N., Lin, S.G., Yu, X.Y., Effect of impaired glucose tolerance on cardiac dysfunction in a rat model of prediabetes. Chin. Med. J. 124 (2011), 734–739.
132. Lajoie, C., Calderone, A., Trudeau, F., Lavoie, N., Massicotte, G., Gagnon, S., Beliveau, L., Exercise training attenuated the PKB and GSK-3 dephosphorylation in the myocardium of ZDF rats. J. Appl. Physiol. 96:2004 (1985), 1606–1612.
133. Lajoie, C., Beliveau, L., Trudeau, F., Lavoie, N., Massicotte, G., Gagnon, S., Calderone, A., The rapid onset of hyperglycaemia in ZDF rats was associated with a widespread alteration of metabolic proteins implicated in glucose metabolism in the heart. Can. J. Physiol. Pharmacol. 84 (2006), 1205–1213.
134. Eto, M., Watanabe, K., Sekiguchi, M., Iwashima, Y., Morikawa, A., Oshima, E., Ishii, K., Metabolic and morphological changes of the heart in Chinese hamsters (CHAD strain) with spontaneous long-term diabetes. Diabetes Res. Clin. Pract. 3 (1987), 297–305.
135. Virkamaki, A., Yki-Jarvinen, H., Allosteric regulation of glycogen synthase and hexokinase by glucosamine-6-phosphate during glucosamine-induced insulin resistance in skeletal muscle and heart. Diabetes 48 (1999), 1101–1107.
136. He, J., Quintana, M.T., Sullivan, J., T, L.P., T, J.G., Schisler, J.C., Hill, J.A., Yates, C.C., Mapanga, R.F., Essop, M.F., Stansfield, W.E., Bain, J.R., Newgard, C.B., Muehlbauer, M.J., Han, Y., Clarke, B.A., Willis, M.S., MuRF2 regulates PPARgamma1 activity to protect against diabetic cardiomyopathy and enhance weight gain induced by a high fat diet. Cardiovasc. Diabetol., 14, 2015, 97.
137. Wang, Z.J., Liu, Q., Li, P.P., Zou, C.H., Shen, Z.F., Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice. Eur. J. Pharmacol. 580 (2008), 277–283.
138. Stanley, W.C., Hall, J.L., Smith, K.R., Cartee, G.D., Hacker, T.A., Wisneski, J.A., Myocardial glucose transporters and glycolytic metabolism during ischemia in hyperglycemic diabetic swine. Metabolism 43 (1994), 61–69.
139. Mansor, L.S., Mehta, K., Aksentijevic, D., Carr, C.A., Lund, T., Cole, M.A., Le Page, L., Sousa Fialho Mda, L., Shattock, M.J., Aasum, E., Clarke, K., Tyler, D.J., Heather, L.C., Increased oxidative metabolism following hypoxia in the type 2 diabetic heart, despite normal hypoxia signalling and metabolic adaptation. J. Physiol. 594 (2016), 307–320.
140. Mansor, L.S., Gonzalez, E.R., Cole, M.A., Tyler, D.J., Beeson, J.H., Clarke, K., Carr, C.A., Heather, L.C., Cardiac metabolism in a new rat model of type 2 diabetes using high-fat diet with low dose streptozotocin. Cardiovasc. Diabetol., 12, 2013, 136.
141. Das, I., Studies on glycogen metabolism in normal and diabetic rat heart in vivo. Can. J. Biochem. 51 (1973), 637–641.
142. Leonard, B.L., Watson, R.N., Loomes, K.M., Phillips, A.R., Cooper, G.J., Insulin resistance in the Zucker diabetic fatty rat: a metabolic characterisation of obese and lean phenotypes. Acta Diabetol. 42 (2005), 162–170.
143. Gannon, M.C., Niewoehner, C.B., Nuttall, F.Q., Effect of insulin administration on cardiac glycogen synthase and synthase phosphatase activity in rats fed diets high in protein, fat or carbohydrate. J. Nutr. 115 (1985), 243–251.
144. Chuffa, L.G., Seiva, F.R., Combined effects of age and diet-induced obesity on biochemical parameters and cardiac energy metabolism in rats. Indian J. Biochem. Biophys. 50 (2013), 40–47.
145. Miller, T.B. Jr., A dual role for insulin in the regulation of cardiac glycogen synthase. J. Biol. Chem. 253 (1978), 5389–5394.
146. Kondomerkos, D.J., Kalamidas, S.A., Kotoulas, O.B., Hann, A.C., Glycogen autophagy in the liver and heart of newborn rats. The effects of glucagon, adrenalin or rapamycin. Histol. Histopathol. 20 (2005), 689–696.
147. Roach, P.J., Depaoli-Roach, A.A., Hurley, T.D., Tagliabracci, V.S., Glycogen and its metabolism: some new developments and old themes. Biochem. J. 441 (2012), 763–787.
148. Jiang, S., Wells, C.D., Roach, P.J., Starch-binding domain-containing protein 1 (Stbd1) and glycogen metabolism: identification of the Atg8 family interacting motif (AIM) in Stbd1 required for interaction with GABARAPL1. Biochem. Biophys. Res. Commun. 413 (2011), 420–425.
149. Reichelt, M.E., Mellor, K.M., Curl, C.L., Stapleton, D., Delbridge, L.M., Myocardial glycophagy - a specific glycogen handling response to metabolic stress is accentuated in the female heart. J. Mol. Cell. Cardiol. 65 (2013), 67–75.
150. Delbridge, L.M., Mellor, K.M., Taylor, D.J., Gottlieb, R.A., Myocardial autophagic energy stress responses—macroautophagy, mitophagy, and glycophagy. Am. J. Phys. Heart Circ. Phys. 308 (2015), H1194–1204.
151. Fayssoil, A., Cardiomyopathy in Pompe's disease. Eur. J. Intern. Med. 19 (2008), 57–59.
152. Cheng, Z., Fang, Q., Danon disease: focusing on heart. J. Hum. Genet. 57 (2012), 407–410.
153. Mellor, K.M., Varma, U., Stapleton, D.I., Delbridge, L.M., Cardiomyocyte glycophagy is regulated by insulin and exposure to high extracellular glucose. Am. J. Phys. Heart Circ. Phys. 306 (2014), H1240–1245.
154. Luiken, J.J., Arumugam, Y., Dyck, D.J., Bell, R.C., Pelsers, M.M., Turcotte, L.P., Tandon, N.N., Glatz, J.F., Bonen, A., Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats. J. Biol. Chem. 276 (2001), 40567–40573.
155. Cook, G.A., Lavrentyev, E.N., Pham, K., Park, E.A., Streptozotocin diabetes increases mRNA expression of ketogenic enzymes in the rat heart. Biochim. Biophys. Acta 1861 (2017), 307–312.
156. de Gonzalo-Calvo, D., van der Meer, R.W., Rijzewijk, L.J., Smit, J.W., Revuelta-Lopez, E., Nasarre, L., Escola-Gil, J.C., Lamb, H.J., Llorente-Cortes, V., Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes. Sci. Rep., 7, 2017, 47.
157. Tauchi-Sato, K., Ozeki, S., Houjou, T., Taguchi, R., Fujimoto, T., The surface of lipid droplets is a phospholipid monolayer with a unique fatty acid composition. J. Biol. Chem. 277 (2002), 44507–44512.
158. Wang, H., Sreenivasan, U., Gong, D.W., O'Connell, K.A., Dabkowski, E.R., Hecker, P.A., Ionica, N., Konig, M., Mahurkar, A., Sun, Y., Stanley, W.C., Sztalryd, C., Cardiomyocyte-specific perilipin 5 overexpression leads to myocardial steatosis and modest cardiac dysfunction. J. Lipid Res. 54 (2013), 953–965.
159. Kuramoto, K., Sakai, F., Yoshinori, N., Nakamura, T.Y., Wakabayashi, S., Kojidani, T., Haraguchi, T., Hirose, F., Osumi, T., Deficiency of a lipid droplet protein, perilipin 5, suppresses myocardial lipid accumulation, thereby preventing type 1 diabetes-induced heart malfunction. Mol. Cell. Biol. 34 (2014), 2721–2731.
160. Demarco, V.G., Ford, D.A., Henriksen, E.J., Aroor, A.R., Johnson, M.S., Habibi, J., Ma, L., Yang, M., Albert, C.J., Lally, J.W., Ford, C.A., Prasannarong, M., Hayden, M.R., Whaley-Connell, A.T., Sowers, J.R., Obesity-related alterations in cardiac lipid profile and nondipping blood pressure pattern during transition to diastolic dysfunction in male db/db mice. Endocrinology 154 (2013), 159–171.
161. Bostrom, P., Andersson, L., Rutberg, M., Perman, J., Lidberg, U., Johansson, B.R., Fernandez-Rodriguez, J., Ericson, J., Nilsson, T., Boren, J., Olofsson, S.O., SNARE proteins mediate fusion between cytosolic lipid droplets and are implicated in insulin sensitivity. Nat. Cell Biol. 9 (2007), 1286–1293.
162. Sollner, T.H., Lipid droplets highjack SNAREs. Nat. Cell Biol. 9 (2007), 1219–1220.
163. Goldberg, I.J., Trent, C.M., Schulze, P.C., Lipid metabolism and toxicity in the heart. Cell Metab. 15 (2012), 805–812.
164. Pulinilkunnil, T., Kienesberger, P.C., Nagendran, J., Waller, T.J., Young, M.E., Kershaw, E.E., Korbutt, G., Haemmerle, G., Zechner, R., Dyck, J.R., Myocardial adipose triglyceride lipase overexpression protects diabetic mice from the development of lipotoxic cardiomyopathy. Diabetes 62 (2013), 1464–1477.
165. Ueno, M., Suzuki, J., Zenimaru, Y., Takahashi, S., Koizumi, T., Noriki, S., Yamaguchi, O., Otsu, K., Shen, W.J., Kraemer, F.B., Miyamori, I., Cardiac overexpression of hormone-sensitive lipase inhibits myocardial steatosis and fibrosis in streptozotocin diabetic mice. Am. J. Physiol. Endocrinol. Metab. 294 (2008), E1109–1118.
166. Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., Tanaka, K., Cuervo, A.M., Czaja, M.J., Autophagy regulates lipid metabolism. Nature 458 (2009), 1131–1135.
167. Battiprolu, P.K., Hojayev, B., Jiang, N., Wang, Z.V., Luo, X., Iglewski, M., Shelton, J.M., Gerard, R.D., Rothermel, B.A., Gillette, T.G., Lavandero, S., Hill, J.A., Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. J. Clin. Invest. 122 (2012), 1109–1118.
168. Paula-Gomes, S., Goncalves, D.A., Baviera, A.M., Zanon, N.M., Navegantes, L.C., Kettelhut, I.C., Insulin suppresses atrophy- and autophagy-related genes in heart tissue and cardiomyocytes through AKT/FOXO signaling. Hormone and metabolic research = Hormon-und Stoffwechselforschung = Hormones et metabolisme 45 (2013), 849–855.
169. How, O.J., Aasum, E., Severson, D.L., Chan, W.Y., Essop, M.F., Larsen, T.S., Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 55 (2006), 466–473.
170. Mazumder, P.K., O'Neill, B.T., Roberts, M.W., Buchanan, J., Yun, U.J., Cooksey, R.C., Boudina, S., Abel, E.D., Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 53 (2004), 2366–2374.
171. Faria, A., Persaud, S.J., Cardiac oxidative stress in diabetes: mechanisms and therapeutic potential. Pharmacol. Ther. 172 (2017), 50–62.
172. Liu, X., Gan, W., Zou, Y., Yang, B., Su, Z., Deng, J., Wang, L., Cai, J., Elevated levels of urinary markers of oxidative DNA and RNA damage in type 2 diabetes with complications. Oxidative Med. Cell. Longev., 2016, 2016, 4323198.
173. Liang, D., Zhong, P., Hu, J., Lin, F., Qian, Y., Xu, Z., Wang, J., Zeng, C., Li, X., Liang, G., EGFR inhibition protects cardiac damage and remodeling through attenuating oxidative stress in STZ-induced diabetic mouse model. J. Mol. Cell. Cardiol. 82 (2015), 63–74.
174. De Blasio, M.J., Huynh, K., Qin, C., Rosli, S., Kiriazis, H., Ayer, A., Cemerlang, N., Stocker, R., Du, X.J., McMullen, J.R., Ritchie, R.H., Therapeutic targeting of oxidative stress with coenzyme Q10 counteracts exaggerated diabetic cardiomyopathy in a mouse model of diabetes with diminished PI3K(p110alpha) signaling. Free Radic. Biol. Med. 87 (2015), 137–147.
175. Nishikawa, T., Sasahara, T., Kiritoshi, S., Sonoda, K., Senokuchi, T., Matsuo, T., Kukidome, D., Wake, N., Matsumura, T., Miyamura, N., Sakakida, M., Kishikawa, H., Araki, E., Evaluation of urinary 8-hydroxydeoxy-guanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes Care 26 (2003), 1507–1512.
176. Huynh, K., Kiriazis, H., Du, X.J., Love, J.E., Jandeleit-Dahm, K.A., Forbes, J.M., McMullen, J.R., Ritchie, R.H., Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes. Diabetologia 55 (2012), 1544–1553.
177. Privratsky, J.R., Wold, L.E., Sowers, J.R., Quinn, M.T., Ren, J., AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension 42 (2003), 206–212.
178. Zhang, M., Kho, A.L., Anilkumar, N., Chibber, R., Pagano, P.J., Shah, A.M., Cave, A.C., Glycated proteins stimulate reactive oxygen species production in cardiac myocytes: involvement of Nox2 (gp91phox)-containing NADPH oxidase. Circulation 113 (2006), 1235–1243.
179. Bombicino, S.S., Iglesias, D.E., Mikusic, I.A., D'Annunzio, V., Gelpi, R.J., Boveris, A., Valdez, L.B., Diabetes impairs heart mitochondrial function without changes in resting cardiac performance. Int. J. Biochem. Cell Biol. 81 (2016), 335–345.
180. Koncsos, G., Varga, Z.V., Baranyai, T., Boengler, K., Rohrbach, S., Li, L., Schluter, K.D., Schreckenberg, R., Radovits, T., Olah, A., Matyas, C., Lux, A., Al-Khrasani, M., Komlodi, T., Bukosza, N., Mathe, D., Deres, L., Bartekova, M., Rajtik, T., Adameova, A., Szigeti, K., Hamar, P., Helyes, Z., Tretter, L., Pacher, P., Merkely, B., Giricz, Z., Schulz, R., Ferdinandy, P., Diastolic dysfunction in prediabetic male rats: role of mitochondrial oxidative stress. Am. J. Phys. Heart Circ. Phys. 311 (2016), H927–H943.
181. Jeong, E.M., Chung, J., Liu, H., Go, Y., Gladstein, S., Farzaneh-Far, A., Lewandowski, E.D., Dudley, S.C. Jr., Role of mitochondrial oxidative stress in glucose tolerance, insulin resistance, and cardiac diastolic dysfunction. J. Am. Heart Assoc., 5, 2016.
182. Kayama, Y., Raaz, U., Jagger, A., Adam, M., Schellinger, I.N., Sakamoto, M., Suzuki, H., Toyama, K., Spin, J.M., Tsao, P.S., Diabetic cardiovascular disease induced by oxidative stress. Int. J. Mol. Sci. 16 (2015), 25234–25263.
183. Huang, C.Y., Ting, W.J., Yang, J.Y., Lin, W.T., Resveratrol attenuated hydrogen peroxide-induced myocardial apoptosis by autophagic flux. Food Nutr. Res., 60, 2016, 30511.
184. Sciarretta, S., Volpe, M., Sadoshima, J., NOX4 regulates autophagy during energy deprivation. Autophagy 10 (2014), 699–701.
185. Sciarretta, S., Zhai, P., Shao, D., Zablocki, D., Nagarajan, N., Terada, L.S., Volpe, M., Sadoshima, J., Activation of NADPH oxidase 4 in the endoplasmic reticulum promotes cardiomyocyte autophagy and survival during energy stress through the protein kinase RNA-activated-like endoplasmic reticulum kinase/eukaryotic initiation factor 2alpha/activating transcription factor 4 pathway. Circ. Res. 113 (2013), 1253–1264.
186. Yuan, H., Perry, C.N., Huang, C., Iwai-Kanai, E., Carreira, R.S., Glembotski, C.C., Gottlieb, R.A., LPS-induced autophagy is mediated by oxidative signaling in cardiomyocytes and is associated with cytoprotection. Am. J. Physiol. Heart Circ. Physiol. 296 (2009), H470–479.
187. Dorn, G.W. 2nd, Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling. Cardiovasc. Res. 81 (2009), 465–473.
188. Kubli, D.A., Gustafsson, A.B., Unbreak my heart: targeting mitochondrial autophagy in diabetic cardiomyopathy. Antioxid. Redox Signal. 22 (2015), 1527–1544.
189. Zhang, C., Syed, T.W., Liu, R., Yu, J., Role of endoplasmic reticulum stress, autophagy, and inflammation in cardiovascular disease. Front. Cardiovasc. Med., 4, 2017, 29.
190. Delbridge, L.M.D., Mellor, K.M., Taylor, D.J., Gottlieb, R.A., Myocardial stress and autophagy: mechanisms and potential therapies. Nat. Rev. Cardiol. 14 (2017), 412–425.
191. Munasinghe, P.E., Riu, F., Dixit, P., Edamatsu, M., Saxena, P., Hamer, N.S., Galvin, I.F., Bunton, R.W., Lequeux, S., Jones, G., Lamberts, R.R., Emanueli, C., Madeddu, P., Katare, R., Type-2 diabetes increases autophagy in the human heart through promotion of Beclin-1 mediated pathway. Int. J. Cardiol. 202 (2016), 13–20.
192. Montaigne, D., Marechal, X., Coisne, A., Debry, N., Modine, T., Fayad, G., Potelle, C., El Arid, J.M., Mouton, S., Sebti, Y., Duez, H., Preau, S., Remy-Jouet, I., Zerimech, F., Koussa, M., Richard, V., Neviere, R., Edme, J.L., Lefebvre, P., Staels, B., Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. Circulation 130 (2014), 554–564.
193. Kanamori, H., Takemura, G., Goto, K., Tsujimoto, A., Mikami, A., Ogino, A., Watanabe, T., Morishita, K., Okada, H., Kawasaki, M., Seishima, M., Minatoguchi, S., Autophagic adaptations in diabetic cardiomyopathy differ between type 1 and type 2 diabetes. Autophagy 11 (2015), 1146–1160.
194. Kobayashi, S., Xu, X., Chen, K., Liang, Q., Suppression of autophagy is protective in high glucose-induced cardiomyocyte injury. Autophagy 8 (2012), 577–592.
195. Zhang, J., Cheng, Y., Gu, J., Wang, S., Zhou, S., Wang, Y., Tan, Y., Feng, W., Fu, Y., Mellen, N., Cheng, R., Ma, J., Zhang, C., Li, Z., Cai, L., Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice. Clin. Sci. (Lond.) 130 (2016), 625–641.
196. Yuan, X., Xiao, Y.C., Zhang, G.P., Hou, N., Wu, X.Q., Chen, W.L., Luo, J.D., Zhang, G.S., Chloroquine improves left ventricle diastolic function in streptozotocin-induced diabetic mice. Drug Des. Dev. Ther. 10 (2016), 2729–2737.
197. Xu, X., Kobayashi, S., Chen, K., Timm, D., Volden, P., Huang, Y., Gulick, J., Yue, Z., Robbins, J., Epstein, P.N., Liang, Q., Diminished autophagy limits cardiac injury in mouse models of type 1 diabetes. J. Biol. Chem. 288 (2013), 18077–18092.
198. Peterson, L.R., Herrero, P., Coggan, A.R., Kisrieva-Ware, Z., Saeed, I., Dence, C., Koudelis, D., McGill, J.B., Lyons, M.R., Novak, E., Davila-Roman, V.G., Waggoner, A.D., Gropler, R.J., Type 2 diabetes, obesity, and sex difference affect the fate of glucose in the human heart. Am. J. Physiol. Heart Circ. Physiol. 308 (2015), H1510–1516.
199. Lyons, M.R., Peterson, L.R., McGill, J.B., Herrero, P., Coggan, A.R., Saeed, I.M., Recklein, C., Schechtman, K.B., Gropler, R.J., Impact of sex on the heart's metabolic and functional responses to diabetic therapies. Am. J. Physiol. Heart Circ. Physiol. 305 (2013), H1584–1591.
200. Warren, S., The effect of insulin on pathologic glycogen deposits in diabetes mellitus. Am. J. Med. Sci. 179 (1930), 482–488.
201. Miller, T.B. Jr., Praderio, M., Wolleben, C., Bullman, J., A hypersensitivity of glycogen phosphorylase activation in hearts of diabetic rats. J. Biol. Chem. 256 (1981), 1748–1753.
202. Tappia, P.S., Thliveris, J., Xu, Y.J., Aroutiounova, N., Dhalla, N.S., Effects of amino acid supplementation on myocardial cell damage and cardiac function in diabetes. Exp. Clin. Cardiol. 16 (2011), e17–22.
203. Mansor, L.S., Sousa Fialho, M.D.L., Yea, G., Coumans, W.A., West, J.A., Kerr, M., Carr, C.A., Luiken, J., Glatz, J.F.C., Evans, R.D., Griffin, J.L., Tyler, D.J., Clarke, K., Heather, L.C., Inhibition of sarcolemmal FAT/CD36 by sulfo-N-succinimidyl oleate rapidly corrects metabolism and restores function in the diabetic heart following hypoxia/reoxygenation. Cardiovasc. Res. 113 (2017), 737–748.
204. Habibi, P., Alihemmati, A., Nasirzadeh, M., Yousefi, H., Habibi, M., Ahmadiasl, N., Involvement of microRNA-133 and -29 in cardiac disturbances in diabetic ovariectomized rats. Iran. J. Basic Med. Sci. 19 (2016), 1177–1185.